Genomic Health Stock Slides 5 Percent After Analyst Cites Regulatory Concern | GenomeWeb
NEW YORK (GenomeWeb News) — Share in Genomic Health were down 4.85 percent, or $1.15, at $22.57,  in mid-afternoon trading today after Lehman Brothers cut the company’s market rating to ‘equal weight’ from ‘overweight.’
 
According to Reuters, an analyst at the investment bank said he expects the company’s share price to fall if the US Food and Drug Administration enacts regulations that would make it more difficult for the company to sell its Oncotype Dx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.